491 related articles for article (PubMed ID: 23757761)
1. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
Ni R; Gillberg PG; Bergfors A; Marutle A; Nordberg A
Brain; 2013 Jul; 136(Pt 7):2217-27. PubMed ID: 23757761
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
3. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease.
Ni R; Gillberg PG; Bogdanovic N; Viitanen M; Myllykangas L; Nennesmo I; Långström B; Nordberg A
Alzheimers Dement; 2017 Apr; 13(4):419-430. PubMed ID: 27693181
[TBL] [Abstract][Full Text] [Related]
4. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
Lemoine L; Gillberg PG; Svedberg M; Stepanov V; Jia Z; Huang J; Nag S; Tian H; Ghetti B; Okamura N; Higuchi M; Halldin C; Nordberg A
Alzheimers Res Ther; 2017 Dec; 9(1):96. PubMed ID: 29229003
[TBL] [Abstract][Full Text] [Related]
5. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
[TBL] [Abstract][Full Text] [Related]
6. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
7. Differential Effects of Structural Modifications on the Competition of Chalcones for the PIB Amyloid Imaging Ligand-Binding Site in Alzheimer's Disease Brain and Synthetic Aβ Fibrils.
Fosso MY; McCarty K; Head E; Garneau-Tsodikova S; LeVine H
ACS Chem Neurosci; 2016 Feb; 7(2):171-6. PubMed ID: 26682772
[TBL] [Abstract][Full Text] [Related]
8. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
Villeneuve S; Rabinovici GD; Cohn-Sheehy BI; Madison C; Ayakta N; Ghosh PM; La Joie R; Arthur-Bentil SK; Vogel JW; Marks SM; Lehmann M; Rosen HJ; Reed B; Olichney J; Boxer AL; Miller BL; Borys E; Jin LW; Huang EJ; Grinberg LT; DeCarli C; Seeley WW; Jagust W
Brain; 2015 Jul; 138(Pt 7):2020-33. PubMed ID: 25953778
[TBL] [Abstract][Full Text] [Related]
9. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
Rabinovici GD; Furst AJ; Alkalay A; Racine CA; O'Neil JP; Janabi M; Baker SL; Agarwal N; Bonasera SJ; Mormino EC; Weiner MW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ
Brain; 2010 Feb; 133(Pt 2):512-28. PubMed ID: 20080878
[TBL] [Abstract][Full Text] [Related]
10. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
11. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
Ni R; Röjdner J; Voytenko L; Dyrks T; Thiele A; Marutle A; Nordberg A
J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
[TBL] [Abstract][Full Text] [Related]
12. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
[TBL] [Abstract][Full Text] [Related]
13. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
14. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
15. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain.
Ni R; Marutle A; Nordberg A
J Alzheimers Dis; 2013; 33(3):841-51. PubMed ID: 23042213
[TBL] [Abstract][Full Text] [Related]
16. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
[TBL] [Abstract][Full Text] [Related]
18. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.
Kreisl WC; Lyoo CH; McGwier M; Snow J; Jenko KJ; Kimura N; Corona W; Morse CL; Zoghbi SS; Pike VW; McMahon FJ; Turner RS; Innis RB;
Brain; 2013 Jul; 136(Pt 7):2228-38. PubMed ID: 23775979
[TBL] [Abstract][Full Text] [Related]
19. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
20. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
